Report Company Directory

BIOBIJOU CO. LTD.

BIOCANCELL LTD

• Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering by GlobeNewsWire
• Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering by GlobeNewsWire
• Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering by GlobeNewsWire
• Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer by GlobeNewsWire
• Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer by GlobeNewsWire
• Anchiano Therapeutics Reports Third Quarter 2018 Financial and Operational Results by GlobeNewsWire
• Anchiano Therapeutics Appoints Dr. Stephen Hoffman and Robert Connelly to Its Board of Directors by GlobeNewsWire
• Anchiano Therapeutics Announces Confidential Submission of Draft Registration Statement for U.S. Initial Public Offering by GlobeNewsWire
• Anchiano Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference by GlobeNewsWire
• Anchiano Therapeutics Appoints Efrat Makov to its Board of Directors by GlobeNewsWire

BioCardia

• BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT) by GlobeNewsWire
• BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA by GlobeNewsWire
• BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno by GlobeNewsWire
• BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress by GlobeNewsWire
• BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality by GlobeNewsWire
• BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results by GlobeNewsWire
• BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial by GlobeNewsWire
• BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 by GlobeNewsWire
• BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial by GlobeNewsWire
• BioCardia Regains Compliance with Nasdaq Listing Requirements by GlobeNewsWire

BioCardia Inc.

• BioCardia Signs Exclusive Development Agreement With AstraZeneca by GlobeNewsWire
• BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery by GlobeNewsWire
• BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange by GlobeNewsWire
• Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia’s Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class by GlobeNewsWire
• BioCardia Reports 2019 First Quarter Financial Results and Business Highlights by GlobeNewsWire
• BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transseptal Access to Heart by GlobeNewsWire
• Daily Insider Ratings Report: Mar 22, 2018 by InsiderInsights.com

Biocartis Group NV

• Persbericht Biocartis Group NV: Biocartis Group NV brengt een update rond de publicatie van haar jaarverslag en de jaarlijkse algemene vergadering by GlobeNewsWire
• Press release Biocartis Group NV: Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting by GlobeNewsWire
• Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) by GlobeNewsWire
• Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) by GlobeNewsWire
• Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion by GlobeNewsWire
• Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting by GlobeNewsWire
• Persbericht Biocartis Group NV: Mededeling betreffende uitwinning door gewaarborgde schuldeisers by GlobeNewsWire
• Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors by GlobeNewsWire
• Persbericht Biocartis Group NV: Vier abstracts, die uitstekende resultaten voor Idylla™ tonen, worden gepresenteerd op het European Society of Molecular Oncology (ESMO) congres by GlobeNewsWire
• Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO) by GlobeNewsWire